[go: up one dir, main page]

BR112018071082A2 - benzodiazepinas nasais e inaladas oralmente - Google Patents

benzodiazepinas nasais e inaladas oralmente

Info

Publication number
BR112018071082A2
BR112018071082A2 BR112018071082A BR112018071082A BR112018071082A2 BR 112018071082 A2 BR112018071082 A2 BR 112018071082A2 BR 112018071082 A BR112018071082 A BR 112018071082A BR 112018071082 A BR112018071082 A BR 112018071082A BR 112018071082 A2 BR112018071082 A2 BR 112018071082A2
Authority
BR
Brazil
Prior art keywords
nasal
benzodiazepines
orally inhaled
orally
inhaled
Prior art date
Application number
BR112018071082A
Other languages
English (en)
Inventor
cooper Brett
Reilly Christopher
Jo Sakata Derek
Graham John
Petersen Karl-Uwe
Bevans Tatjana
Stöhr Thomas
Original Assignee
Paion Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paion Uk Ltd filed Critical Paion Uk Ltd
Publication of BR112018071082A2 publication Critical patent/BR112018071082A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Anesthesiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção está relacionada ao produto farmacológico nasal e inalado oralmente (oindp) que compreende uma benzodiazepina, em particular remimazolam.
BR112018071082A 2016-04-14 2017-04-18 benzodiazepinas nasais e inaladas oralmente BR112018071082A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
LU93027 2016-04-14
PCT/EP2017/059214 WO2017178663A1 (en) 2016-04-14 2017-04-18 Orally inhaled and nasal benzodiazepines

Publications (1)

Publication Number Publication Date
BR112018071082A2 true BR112018071082A2 (pt) 2019-02-05

Family

ID=55949007

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018071082A BR112018071082A2 (pt) 2016-04-14 2017-04-18 benzodiazepinas nasais e inaladas oralmente

Country Status (12)

Country Link
US (3) US20190175613A1 (pt)
EP (1) EP3442539A1 (pt)
JP (2) JP2019513796A (pt)
KR (1) KR20180131617A (pt)
CN (1) CN109641000A (pt)
AU (1) AU2017248683A1 (pt)
BR (1) BR112018071082A2 (pt)
CA (1) CA3020722A1 (pt)
EA (1) EA036520B1 (pt)
IL (1) IL262087B (pt)
MX (1) MX2018012498A (pt)
WO (1) WO2017178663A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111346065B (zh) * 2018-12-21 2022-05-20 宜昌人福药业有限责任公司 苯二氮䓬类化合物口腔用固体药物组合物及其制备方法
CN111346098B (zh) * 2018-12-21 2022-05-27 宜昌人福药业有限责任公司 苯二氮䓬类化合物局部用药物组合物及制备方法和用途
CN111346058B (zh) * 2018-12-21 2022-05-17 宜昌人福药业有限责任公司 一种苯二氮䓬类化合物经鼻粘膜给药的药物组合物及其制备方法和用途
EP3714884A1 (en) 2019-03-27 2020-09-30 Paion UK Limited Medical uses for benzodiazepines with a particular eeg pattern
CN112209932B (zh) * 2019-07-12 2023-03-24 成都倍特药业股份有限公司 一种化合物氢溴酸盐的新固体形态及其制备方法和用途
CN112462015B (zh) * 2020-11-18 2022-07-12 海南倍特药业有限公司 一种氢溴酸瑞马唑仑细菌内毒素的检测方法
CN112402428B (zh) * 2020-11-26 2022-02-25 李依泽 瑞马唑仑在制备治疗阿片类药物诱发的术后痛觉过敏的药物中的应用
CN114588164B (zh) * 2022-04-19 2023-08-11 天津医科大学总医院 瑞马唑仑在预防围术期低体温和寒战中的应用
WO2024126745A1 (en) * 2022-12-16 2024-06-20 Lts Lohmann Therapie-Systeme Ag Oromucosal delivery system containing remimazolam

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4950664A (en) * 1988-09-16 1990-08-21 Rugby-Darby Group Companies, Inc. Nasal administration of benzodiazepine hypnotics
CA2143246C (en) 1994-03-16 2000-08-22 Thierry Godel Imidazodiazepines
DK0801651T3 (da) 1995-01-06 2001-10-22 Hoffmann La Roche Hydroxymethyl-imidazodiazepiner og deres estere
AU4382896A (en) 1995-02-02 1996-08-21 F. Hoffmann-La Roche Ag Acetylimidazobenzodiazepines
GB9911152D0 (en) 1999-05-14 1999-07-14 Glaxo Group Ltd Short-acting benzodiazepines
US7160880B1 (en) * 1999-05-14 2007-01-09 Cenes Limited Short-acting benzodiazepines
GB0613693D0 (en) 2006-07-10 2006-08-16 Cenes Ltd Benzodiazepine salts (3)
GB0613692D0 (en) * 2006-07-10 2006-08-16 Cenes Ltd Benzodiazepine salts
BRPI0714886B8 (pt) * 2006-07-10 2021-05-25 Paion Uk Ltd sais de benzodiazepina, seus usos e seus processos de preparação, e composição farmacêutica
GB0716907D0 (en) * 2007-08-31 2007-10-10 Archimedes Dev Ltd Pharmaceutical powder compositions
EP2305647A1 (en) * 2009-09-18 2011-04-06 PAION UK Limited Process for preparing 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4 H-imidazo[1,2-a][1,4]benzodiazepine-4-yl] propionic acid methyl ester or the benzene sulfonate salt thereof, and compounds useful in that process
EP2450039A1 (en) * 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
WO2012075286A2 (en) * 2010-12-01 2012-06-07 The Regents Of The University Of California Intrapulmonary benzodiazepine for the treatment and prevention of seizures
US20140128379A1 (en) * 2011-04-01 2014-05-08 Cpex Pharmaceuticals, Inc. Nasal formulations of benzodiazepine
CN102964349A (zh) 2011-08-31 2013-03-13 江苏恒瑞医药股份有限公司 苯并二氮杂*衍生物的托西酸盐及其多晶型、它们的制备方法和用途
MY185117A (en) * 2012-05-22 2021-04-30 Paion Uk Ltd Compositions comprising short-acting benzodiazepines
MX2015002467A (es) * 2012-08-31 2015-11-09 Paion Uk Ltd Regimen de dosificacion de un sedante.
AR094963A1 (es) 2013-03-04 2015-09-09 Ono Pharmaceutical Co Reacción de oxidación excelente en el índice de conversión
CN103232454A (zh) * 2013-05-05 2013-08-07 王元青 治疗精神疾病的药物
CN107198691A (zh) * 2016-03-17 2017-09-26 江苏恒瑞医药股份有限公司 一种瑞马唑仑的药物组合物

Also Published As

Publication number Publication date
IL262087A (en) 2018-11-29
IL262087B (en) 2021-09-30
AU2017248683A1 (en) 2018-10-25
CA3020722A1 (en) 2017-10-19
CN109641000A (zh) 2019-04-16
MX2018012498A (es) 2019-07-01
JP2019513796A (ja) 2019-05-30
JP2021185170A (ja) 2021-12-09
US20190175613A1 (en) 2019-06-13
US20200253983A1 (en) 2020-08-13
EA036520B1 (ru) 2020-11-19
KR20180131617A (ko) 2018-12-10
EA201892327A1 (ru) 2019-04-30
EP3442539A1 (en) 2019-02-20
WO2017178663A1 (en) 2017-10-19
US20220273672A1 (en) 2022-09-01

Similar Documents

Publication Publication Date Title
BR112018071082A2 (pt) benzodiazepinas nasais e inaladas oralmente
MX2018013504A (es) Metodos de fabricacion, composiciones y aplicaciones medicas de productos farmaceuticos de cannabis administrables oralmente.
CY1120529T1 (el) Προφαρμακα φουμαρικων αλατων και η χρηση τους στην αγωγη ποικιλων νοσων
PH12019501970A1 (en) Pharmaceutical compositions for combination therapy
IL263709A (en) Methods for the manufacture of cannabinoid prodrugs, pharmaceutical formulations and their use
BR112015024411A2 (pt) desaza-purinonas macrocíclicas para o tratamento de infeções virais
IL252418A0 (en) Venom injury treatment and pharmaceutical preparations, systems and kits related to treatment
PH12019501301A1 (en) Pharmaceutical compositions for combination therapy
CO2017002472A2 (es) Formulación de acetato de abiraterona
MX2017002239A (es) Composicion que contiene cineol para la administracion nasal.
IL261982B (en) A prophylactic and therapeutic preparation based on peroxaphthalate, especially a pharmaceutical preparation
EP3307265A4 (en) Pharmaceutical combination and uses thereof
CL2019000563S1 (es) Envase y dispendio de medicamentos. (divisional solicitud 201800718)
BR112016023754A2 (pt) ?uso de lactobacillus paracasei para promover recuperação da diversidade da microbiota intestinal após disbiose?
CO2017001601A2 (es) Derivados de 1-acetil-4-((pirazin-2-il) amino)-1,2,3,4-tetrahydroquinolina-6 carboxamida como inhibidores de bromodominio
MA45457A (fr) Médicament ophtalmique contenant du salbutamol.
EP3623384A4 (en) ANTI-CLDN-5 ANTIBODY AND ACTIVE SUBSTANCE WITH THIS ANTIBODY
WO2014154844A8 (de) Stabilisiertes polyribonucleotid codierend für ein elastisches faserprotein
PH12017501979A1 (en) Pharmaceutical compound
PH12016502284A1 (en) Cough medicine containing ambroxol hydrochloride
HUE057090T2 (hu) BI-heteroaril-szubsztituált 1,4-benzodiazepinek és alkalmazásuk rák kezelésében
IN2013MU03370A (pt)
CO2018004191A2 (es) Productos de construcción con grafeno u óxido de grafeno
MX2015013231A (es) Composiciones que disuaden el abuso y metodos de utilizacion.
UA106117C2 (uk) Спосіб одержання лікувально-профілактичного засобу із протисудомною дією

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements